Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia A

1 Dec 2016

Abstract excerpt

Turoctocog alfa pegol (N8-GP) is a novel glycoPEGylated extended half-life recombinant factor VIII (FVIII) product developed for prophylaxis and treatment of bleeds in patients with haemophilia A, to enable higher activity levels with less frequent injections compared with standard FVIII products. This phase III (NCT01480180), multinational, open-label, non-randomised trial evaluated the safety and clinical...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Blood Coagulation and Thrombosis Mechanisms
Share to Hemophilia Treatment and Research

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 27904904
DOI: 10.1160/th16-06-0444

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia APMID 27904904Read ↗

Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trialSemantic proximity Read ↗

Efficacy, safety, and immunogenicity of rurioctocog alfa pegol for prophylactic treatment in previously treated patients with severe hemophilia A: a systematic review and meta-analysis of clinical trialsSemantic proximity Read ↗

Many factor VIII products available in the treatment of hemophilia A: an embarrassment of riches?Semantic proximity Read ↗

Safety and efficacy of turoctocog alfa in the prevention and treatment of bleeds in previously untreated paediatric patients with severe haemophilia A: Results from the guardian 4 multinational clinical trial.Semantic proximity Read ↗

Giroctocogene fitelparvovec gene therapy for severe hemophilia A: 104-week analysis of the phase 1/2 Alta studySemantic proximity Read ↗

The Evolution of Hemophilia Care: Clinical and Laboratory Advances, Opportunities, and ChallengesSemantic proximity Read ↗

Long‐term safety and efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with haemophilia ASemantic proximity Read ↗

Three-year outcomes of valoctocogene roxaparvovec gene therapy for hemophilia ASemantic proximity Read ↗

Efficacy, safety, and quality of life 4 years after valoctocogene roxaparvovec gene transfer for severe hemophilia A in the phase 3 GENEr8-1 trialSemantic proximity Read ↗

Navigation of the Hemophilia Drug Choice-Paralysis: A Quick User Guide to New and Existing TherapiesSemantic proximity Read ↗

The incidence and treatment of bleeding episodes in non-severe haemophilia A patients with inhibitors.Semantic proximity Read ↗

Gene Therapy with Etranacogene Dezaparvovec for Hemophilia BSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.